Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 12/20 | 0.48 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.46 |
| ▸ | GIPR | P48546 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | IDH1 | O75874 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2652311 | 0.88 | HDAC1 (0.47) | GCGREGLN1HDAC1HDAC8GIPR | |
| SCHEMBL2655339 | 0.85 | HDAC1 (0.46) | GCGREGLN1HDAC1HDAC8 | |
| SCHEMBL2651211 | 0.82 | GCGR (0.56) | GCGREGLN1GIPRCYP3A4CYP2C8 | |
| SCHEMBL2652327 | 0.78 | PTGER4 (0.49) | GCGREGLN1GIPRCYP3A4CYP2C8 | |
| SCHEMBL2652185 | 0.78 | GCGR (0.60) | GCGRGIPRCYP3A4CYP2C8CYP2C9 | |
| SCHEMBL7116449 | 0.77 | GCGR (0.50) | GCGREGLN1GIPRIDH1 | |
| SCHEMBL2652304 | 0.76 | GCGR (0.50) | GCGRGIPRCYP3A4CYP2C8CYP2C9 | |
| SCHEMBL2665495 | 0.76 | GCGR (0.47) | GCGRGIPRCYP3A4CYP2C8CYP2C9 | |
| SCHEMBL2654491 | 0.74 | NAMPT (0.51) | GCGRHDAC1HDAC8CYP3A4CYP2C9 | |
| SCHEMBL4989051 | 0.74 | TP53 (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030212119-A1 | Novel glucagon receptor antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2003-11-13 | — | — | US | disclosed |
| WO-2003053938-A1 | BENZIMIDAZOLS AND INDOLS AS GLUCAGON RECEPTOR ANTAGONISTS/INVERSE AGONISTEN | NOVO NORDISK A/S (DK) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212119-A1 | Novel glucagon receptor antagonists/inverse agonists | GLP1R, GCGR, GIPR | GCGR 2/4885EGLN1 2105/4885HDAC1 3760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.